Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux. Weiler's extensive background spans key roles at Exzell Pharma, Biosyent Inc.,…
Peter J. Weiler appointed as new CFO of Edesa Biotech, starting May 1, 2025. Weiler brings extensive experience, with previous roles at Exzell Pharma and Biosyent Inc. Weiler holds an…
A pivotal leadership change occurs at Edesa Biotech as Peter J. Weiler is appointed CFO, bringing extensive experience in business development and pharmaceutical leadership. Weiler's background includes key roles at…
Peter J. Weiler joins Edesa Biotech as CFO on May 1, 2025, bringing extensive leadership in biotechnology and pharmaceuticals. Weiler's experience includes roles as President of Exzell Pharma and VP…
Edesa Biotech appoints Peter J. Weiler as the new CFO, effective May 1, 2025, signaling a strategic shift. Weiler brings a robust track record in biotech and pharma, previously leading…
Wacker Biotech and RNAV8 Bio have formed a strategic alliance to advance mRNA-based therapies. The partnership combines Wacker’s biopharma manufacturing expertise with RNAV8’s mRNA engineering capabilities. Focus is placed on…
Edesa Biotech has appointed Peter J. Weiler as the new Chief Financial Officer, marking a pivotal moment for the company's growth and innovation. Weiler brings extensive experience in the pharmaceutical…
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Wacker Biotech and RNAV8 Bio have embarked on a transformative mRNA technology partnership, aiming to revolutionize medicine. Wacker Biotech brings advanced microbial fermentation capabilities, enhancing pharmaceutical protein and pDNA production.…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 2025, succeeding Stephen Lemieux. Weiler brings extensive experience in corporate finance and strategic development from Exzell…